JP2020525536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525536A5 JP2020525536A5 JP2020517774A JP2020517774A JP2020525536A5 JP 2020525536 A5 JP2020525536 A5 JP 2020525536A5 JP 2020517774 A JP2020517774 A JP 2020517774A JP 2020517774 A JP2020517774 A JP 2020517774A JP 2020525536 A5 JP2020525536 A5 JP 2020525536A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- stimulant
- vector
- cell
- sre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 32
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 239000013598 vector Substances 0.000 claims description 23
- 108091033319 polynucleotide Proteins 0.000 claims description 17
- 239000002157 polynucleotide Substances 0.000 claims description 17
- 102000040430 polynucleotide Human genes 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 11
- 239000002955 immunomodulating agent Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000012636 effector Substances 0.000 claims description 10
- 229960000835 tadalafil Drugs 0.000 claims description 10
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 8
- 150000003384 small molecules Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- RCJYGWGQCPDYSL-HZPDHXFCSA-N 7-[(3-bromo-4-methoxyphenyl)methyl]-1-ethyl-8-[[(1r,2r)-2-hydroxycyclopentyl]amino]-3-(2-hydroxyethyl)purine-2,6-dione Chemical compound C=1C=C(OC)C(Br)=CC=1CN1C=2C(=O)N(CC)C(=O)N(CCO)C=2N=C1N[C@@H]1CCC[C@H]1O RCJYGWGQCPDYSL-HZPDHXFCSA-N 0.000 claims description 4
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000307 avanafil Drugs 0.000 claims description 4
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims description 4
- 229950004399 beminafil Drugs 0.000 claims description 4
- ZISFCTXLAXIEMV-UHFFFAOYSA-N benzamidenafil Chemical compound C1=C(OC)C(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1NC(C)CO ZISFCTXLAXIEMV-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- KJJPAVCZQWWWMM-WKILWMFISA-N chembl2107736 Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC([C@@H]2CC[C@H](CC2)C(O)=O)=NC2=C1C1=CC=CC=C1S2 KJJPAVCZQWWWMM-WKILWMFISA-N 0.000 claims description 4
- 229950003418 dasantafil Drugs 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- -1 rodenafil Chemical compound 0.000 claims description 4
- 229960003310 sildenafil Drugs 0.000 claims description 4
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 claims description 4
- 229960000438 udenafil Drugs 0.000 claims description 4
- 229960002381 vardenafil Drugs 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 108091027981 Response element Proteins 0.000 claims description 3
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 claims description 3
- 101710095785 cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 claims description 3
- 230000003197 catalytic effect Effects 0.000 claims description 3
- 230000000368 destabilizing effect Effects 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000000021 stimulant Substances 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 239000013607 AAV vector Substances 0.000 claims 1
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 229950002245 mirodenafil Drugs 0.000 claims 1
- MIJFNYMSCFYZNY-UHFFFAOYSA-N mirodenafil Chemical compound C1=C(C=2NC=3C(CCC)=CN(CC)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)N1CCN(CCO)CC1 MIJFNYMSCFYZNY-UHFFFAOYSA-N 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 20
- 230000037396 body weight Effects 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 241001193851 Zeta Species 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023133318A JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518078P | 2017-06-12 | 2017-06-12 | |
| US62/518,078 | 2017-06-12 | ||
| US201762523850P | 2017-06-23 | 2017-06-23 | |
| US201762523862P | 2017-06-23 | 2017-06-23 | |
| US62/523,862 | 2017-06-23 | ||
| US62/523,850 | 2017-06-23 | ||
| US201762555313P | 2017-09-07 | 2017-09-07 | |
| US62/555,313 | 2017-09-07 | ||
| PCT/US2018/037005 WO2018231759A1 (en) | 2017-06-12 | 2018-06-12 | Pde5 compositions and methods for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133318A Division JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020525536A JP2020525536A (ja) | 2020-08-27 |
| JP2020525536A5 true JP2020525536A5 (enExample) | 2021-07-26 |
| JP7362596B2 JP7362596B2 (ja) | 2023-10-17 |
Family
ID=64660633
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517774A Active JP7362596B2 (ja) | 2017-06-12 | 2018-06-12 | 免疫療法のためのｐｄｅ５組成物及び方法 |
| JP2023133318A Pending JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023133318A Pending JP2023144094A (ja) | 2017-06-12 | 2023-08-18 | 免疫療法のためのｐｄｅ５組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11241485B2 (enExample) |
| EP (1) | EP3638289A4 (enExample) |
| JP (2) | JP7362596B2 (enExample) |
| CN (1) | CN111107866A (enExample) |
| CA (1) | CA3067211A1 (enExample) |
| MA (1) | MA49403A (enExample) |
| MX (1) | MX2019014960A (enExample) |
| SG (1) | SG11201912010XA (enExample) |
| WO (1) | WO2018231759A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
| US11253546B2 (en) * | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2018227583B2 (en) * | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| AU2018273796A1 (en) * | 2017-05-23 | 2020-01-16 | Biovite Australia Pty Ltd | Extracts from Arthrospira and uses thereof |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| MA49403A (fr) | 2017-06-12 | 2021-03-24 | Obsidian Therapeutics Inc | Compositions de pde5 et méthodes d'immunothérapie |
| WO2018237323A1 (en) * | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pde5a destabilizing domains |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| CA3098128A1 (en) | 2018-04-18 | 2019-10-24 | Ucl Business Ltd | Engineered regulatory t cell |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3813878A4 (en) | 2018-06-14 | 2022-03-16 | 2seventy bio, Inc. | CAR ANTI-BCMA ANTIBODIES, CONJUGATES AND METHODS OF USE |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| WO2020123716A1 (en) * | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| EP3912992A4 (en) | 2019-02-04 | 2022-11-23 | National University Corporation Ehime University | Car library and production method for scfv |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| CA3132817A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Cd40l compositions and methods for tunable regulation |
| WO2020210665A1 (en) * | 2019-04-12 | 2020-10-15 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with cd20 safety switch |
| JP7675016B2 (ja) * | 2019-05-08 | 2025-05-12 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対するヒト化抗体およびそれを使用する方法 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP3976659A4 (en) * | 2019-05-24 | 2023-02-22 | Memorial Sloan Kettering Cancer Center | Anti-glypican-3 antibodies and uses thereof |
| WO2021034952A1 (en) * | 2019-08-19 | 2021-02-25 | Elpis Biopharmaceuticals | Anti-cd19 antibodies and uses thereof |
| CN114765980A (zh) * | 2019-09-06 | 2022-07-19 | 加利福尼亚大学董事会 | 用于治疗癌症的嵌合抗原受体及相关方法和组合物 |
| WO2021050789A1 (en) * | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| JP7744335B2 (ja) * | 2019-10-11 | 2025-09-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ヒトサイトメガロウイルスに対するキメラ抗原受容体 |
| CA3161573A1 (en) * | 2019-12-12 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-drug conjugates specific for cd276 and uses thereof |
| US20230030085A1 (en) * | 2019-12-16 | 2023-02-02 | 2Seventy Bio, Inc. | Anti-bcma car antibodies, conjugates, and methods of use |
| AU2020407235A1 (en) * | 2019-12-20 | 2022-07-07 | Poseida Therapeutics, Inc. | Anti-MUC1 compositions and methods of use |
| KR20220139319A (ko) | 2020-01-08 | 2022-10-14 | 옵시디안 테라퓨틱스, 인크. | 조정 가능한 전사의 조절을 위한 조성물 및 방법 |
| WO2021167723A1 (en) * | 2020-02-17 | 2021-08-26 | Board Of Regents, The University Of Texas System | Chimeric scavenger receptors targeted to phosphorylated tau (ptau) and uses thereof |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| WO2021175250A1 (en) * | 2020-03-03 | 2021-09-10 | Aptorum Therapeutics Limited | Compounds and methods for treating diseases and/or conditions caused by coronavirus |
| WO2021202941A1 (en) * | 2020-04-03 | 2021-10-07 | University Of Cincinnati | Secreted phosphorylated heat shock protein-70 as a biomarker for treating and diagnosing cancer |
| WO2021216686A1 (en) * | 2020-04-21 | 2021-10-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Treating and curing covid-19 infection utilizing a laser |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| US12012458B2 (en) * | 2020-06-12 | 2024-06-18 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
| EP4168053A1 (en) | 2020-06-22 | 2023-04-26 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of cas nucleases |
| WO2022006588A1 (en) * | 2020-06-29 | 2022-01-06 | Trustees Of Tufts College | Il-38 and analogues thereof for treatment of neuro-inflammatory and neurodegenerative diseases |
| US11508453B2 (en) * | 2020-08-18 | 2022-11-22 | Micron Technology, Inc. | Encoding test data of microelectronic devices, and related methods, devices, and systems |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN116981697A (zh) * | 2021-01-14 | 2023-10-31 | 森迪生物科学公司 | 可分泌有效载荷调节 |
| AU2022211438A1 (en) | 2021-01-19 | 2023-08-17 | Obsidian Therapeutics, Inc. | Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereof |
| WO2022187710A1 (en) | 2021-03-05 | 2022-09-09 | Atreca, Inc. | Epha2 antibodies |
| US20240218069A1 (en) * | 2021-04-28 | 2024-07-04 | Lyvgen Biopharma Holdings Limited | Bi-specific antibodies comprising anti-b7h3 binding molecules |
| CA3218215A1 (en) * | 2021-05-19 | 2022-11-24 | Biliang HU | Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such |
| EP4372089A4 (en) * | 2021-07-16 | 2025-07-09 | Noile Immune Biotech Inc | CHIMERIC ANTIGEN RECEPTOR, CELL EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR CONTAINING A BASE SEQUENCE ENCODING SAID CHIMERIC ANTIGEN RECEPTOR |
| CN113564184B (zh) * | 2021-07-16 | 2023-04-18 | 昆明理工大学 | 一种天麻谷氨酰胺合成酶基因及其应用 |
| IL309914A (en) | 2021-07-29 | 2024-03-01 | Takeda Pharmaceuticals Co | Immune cells express a chimeric antigen receptor that specifically targets mesothelin and their uses |
| CA3233380A1 (en) | 2021-10-18 | 2023-04-27 | Dhruv SETHI | Compositions and systems for regulation of function/abundance and delivery of polypeptide payloads |
| US20250134928A1 (en) | 2022-01-18 | 2025-05-01 | Obsidian Therapeutics, Inc. | Methods for identifying and using allogeneic tumor infiltrating lymphocytes to treat cancer |
| CN114606323B (zh) * | 2022-04-24 | 2023-11-10 | 深圳大学 | 一种识别胃癌干细胞的标志物lgsn作为胃癌诊断和治疗靶标的应用 |
| JP2025516189A (ja) * | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| CN116063507A (zh) * | 2022-05-11 | 2023-05-05 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| WO2024011104A1 (en) | 2022-07-05 | 2024-01-11 | Neomics Pharmaceuticals Llc | Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain |
| EP4374872A1 (en) * | 2022-11-22 | 2024-05-29 | Koninklijke Philips N.V. | Pde enhanced car-t cells |
| CN117482245B (zh) * | 2022-12-30 | 2024-10-29 | 英百瑞(杭州)生物医药有限公司 | 抗5t4抗体-自然杀伤细胞偶联物及其用途 |
| WO2024165024A1 (zh) * | 2023-02-09 | 2024-08-15 | 星尘生物科技(上海)有限公司 | 一种嵌合抗原受体及其应用 |
| CN116004547B (zh) * | 2023-03-06 | 2025-04-25 | 浙江康佰裕生物科技有限公司 | 一种辐照car-t细胞及其制备方法与应用 |
| EP4474016A1 (en) | 2023-06-07 | 2024-12-11 | Julius-Maximilians-Universität Würzburg | Strategies to target extracellularly accessible ras protein |
| WO2025049981A1 (en) * | 2023-09-01 | 2025-03-06 | Institute For Environmental Health, Inc. | Variably deamidated gluten polypeptides and antibodies against same |
| WO2025051339A1 (en) * | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| WO2025072355A1 (en) * | 2023-09-25 | 2025-04-03 | Biohybrid Solutions Holdings, Inc. | Methods for and compositions of non-peg bioconjugates with ultra-high drug-to-agent ratio |
| WO2025122943A1 (en) | 2023-12-08 | 2025-06-12 | Obsidian Therapeutics, Inc. | Compositions and methods for enhanced payload regulation using nuclear factor of activated t cells (nfat) response elements |
| WO2025144887A1 (en) | 2023-12-27 | 2025-07-03 | Obsidian Therapeutics, Inc. | Compositions and methods for tunable regulation of il15 and light |
| CN119930817B (zh) * | 2024-12-24 | 2025-12-02 | 国科大杭州高等研究院 | Tigit全人源抗体及其制备方法与应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023091A2 (en) * | 1998-10-15 | 2000-04-27 | Bioimage A/S | Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| WO2003054150A2 (en) | 2001-12-07 | 2003-07-03 | The Ohio State University Research Foundation | Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder |
| US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| US20090087871A1 (en) | 2004-05-28 | 2009-04-02 | Atlanta Pharma Ag | Method for Identifying PDE5-Modulators |
| WO2007142929A2 (en) | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
| US8173792B2 (en) | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
| US8530636B2 (en) | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
| EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US20140255361A1 (en) * | 2013-03-07 | 2014-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Estrogen-receptor based ligand system for regulating protein stability |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US20170291934A1 (en) | 2014-09-22 | 2017-10-12 | Charles C. Reed | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| US9766255B2 (en) * | 2015-01-12 | 2017-09-19 | President And Fellows Of Harvard College | Biosensors engineered from conditionally stable ligand-binding domains |
| US11655452B2 (en) | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| EP3331905B1 (en) * | 2015-08-06 | 2022-10-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US11052111B2 (en) * | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
| AU2018227583B2 (en) | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| JP7660343B2 (ja) | 2017-03-03 | 2025-04-11 | オブシディアン セラピューティクス， インコーポレイテッド | 免疫療法のための組成物及び方法 |
| WO2018161026A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| WO2018161038A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il12 compositions and methods for immunotherapy |
| MA49403A (fr) | 2017-06-12 | 2021-03-24 | Obsidian Therapeutics Inc | Compositions de pde5 et méthodes d'immunothérapie |
| WO2018237323A1 (en) * | 2017-06-23 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pde5a destabilizing domains |
-
2018
- 2018-06-12 MA MA049403A patent/MA49403A/fr unknown
- 2018-06-12 JP JP2020517774A patent/JP7362596B2/ja active Active
- 2018-06-12 EP EP18817018.7A patent/EP3638289A4/en active Pending
- 2018-06-12 SG SG11201912010XA patent/SG11201912010XA/en unknown
- 2018-06-12 US US16/621,593 patent/US11241485B2/en active Active
- 2018-06-12 CN CN201880051747.6A patent/CN111107866A/zh active Pending
- 2018-06-12 CA CA3067211A patent/CA3067211A1/en active Pending
- 2018-06-12 MX MX2019014960A patent/MX2019014960A/es unknown
- 2018-06-12 WO PCT/US2018/037005 patent/WO2018231759A1/en not_active Ceased
-
2022
- 2022-02-01 US US17/649,592 patent/US11666642B2/en active Active
-
2023
- 2023-08-18 JP JP2023133318A patent/JP2023144094A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525536A5 (enExample) | ||
| JP2020511529A5 (enExample) | ||
| US10865382B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| JP7148539B2 (ja) | 免疫抱合体 | |
| US11274140B2 (en) | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof | |
| JP7386083B2 (ja) | Ｃｄ８０バリアント免疫調節タンパク質及びその使用 | |
| AU2020336131B2 (en) | Chimeric cytokine receptors comprising TGF beta binding domains | |
| JP7282760B2 (ja) | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| US20230071889A1 (en) | Bifunctional anti-pd-1/il-7 molecule | |
| CA3087149A1 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| US20210177951A1 (en) | Engineered cells & methods | |
| JP2020511528A5 (enExample) | ||
| JP2017538710A5 (enExample) | ||
| JP2017522882A5 (enExample) | ||
| US11773384B2 (en) | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells | |
| CA3103337A1 (en) | Nef-containing t cells and methods of producing thereof | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| US20240317815A1 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| US20230321239A1 (en) | Chimeric antigen receptor t cells for treating autoimmunity | |
| US20250019411A1 (en) | T-Cell Engaging Polypeptides and Methods of Use Thereof | |
| JPWO2022046730A5 (enExample) | ||
| WO2025081163A1 (en) | Compositions for the treatment of cancer | |
| TW202436341A (zh) | 嵌合抗原受體及抗體—ｎｋｇ２ｄ配位體域融合蛋白 | |
| JP2025540251A (ja) | 血液癌の治療において使用するためのキット | |
| HK40020606A (en) | Pd-l1 variant immunomodulatory proteins and uses thereof |